Literature DB >> 30498410

Low-Volume Leukapheresis in Non-Cytokine-Stimulated Donors for the Collection of Mononuclear Cells.

Adamma Anyanwu1, Nicole Sitzmann1, Svetlana Hetjens2, Harald Klüter1, Patrick Wuchter1.   

Abstract

BACKGROUND: There is an increasing demand for products containing mononuclear cells (MNCs) for cellular immune therapy. Hence, leukapheresis is increasingly performed in healthy volunteer donors.
METHODS: We evaluated 147 low-volume leukapheresis procedures from 77 healthy non-cytokine-stimulated donors. Complete blood counts (CBCs) of the donors were measured before and directly after the procedures as well as from the MNC products. Follow-up CBCs were collected from donors within 21 days.
RESULTS: The product hematocrit within a range from 1.2 to 6.0% did not correlate with the collection efficiency of any cell population or the granulocyte and platelet yield. There was a strong correlation between the CBC values before leukapheresis and the cell yield of lymphocytes and monocytes as well as a perfect negative correlation between cell recruitment and cell loss in all cell populations. Furthermore, we observed a significant decrease in the CBC values in all cell populations directly after leukapheresis, which recovered within a mean of 16.1 days (SD ± 2.1 days) and even showed a significant increase in granulocytes and platelets.
CONCLUSION: Low-volume leukapheresis is feasible for the collection of MNCs in which the product hematocrit is negligible for the collection efficiency, cell yield, or contamination of residual cells under operational settings recommended by the manufacturer. Our data suggests that cell recruitment is regulated by the number of cells removed, which may also be the stimulus to induce granulo- and thrombopoiesis within the first days after leukapheresis.

Entities:  

Keywords:  Apheresis; Donors; MNC; Spectra Optia

Year:  2018        PMID: 30498410      PMCID: PMC6257153          DOI: 10.1159/000490859

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  22 in total

1.  Comparison of two apheresis systems for the collection of CD14+ cells intended to be used in dendritic cell culture.

Authors:  Erwin F Strasser; Thomas G Berger; Volker Weisbach; Robert Zimmermann; Jürgen Ringwald; Beatrice Schuler-Thurner; Jürgen Zingsem; Reinhold Eckstein
Journal:  Transfusion       Date:  2003-09       Impact factor: 3.157

2.  Mononuclear cell variability and recruitment in non-cytokine-stimulated donors after serial 10-liter leukapheresis procedures.

Authors:  Erwin F Strasser; Robert Zimmermann; Volker Weisbach; Jürgen Ringwald; Jürgen Zingsem; Reinhold Eckstein
Journal:  Transfusion       Date:  2005-03       Impact factor: 3.157

3.  Monocyte enriched apheresis for preparation of dendritic cells (DC) to be used in cellular therapy.

Authors:  Anna Svensson; Lars Adamson; Pavel Pisa; Max Petersson; Mona Hansson
Journal:  Transfus Apher Sci       Date:  2005-10       Impact factor: 1.764

4.  Evolution of MNC and lymphocyte collection settings employing different Spectra Optia® Leukapheresis systems.

Authors:  M Punzel; A Kozlova; A Quade; A H Schmidt; R Smith
Journal:  Vox Sang       Date:  2017-08-14       Impact factor: 2.144

5.  Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection.

Authors:  Katharina Lisenko; Petra Pavel; Thomas Bruckner; Joe Puthenparambil; Michael Hundemer; Anita Schmitt; Mathias Witzens-Harig; Anthony D Ho; Patrick Wuchter
Journal:  J Clin Apher       Date:  2016-04-20       Impact factor: 2.821

6.  Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures.

Authors:  F Sanderson; P Poullin; R Smith; C Nicolino-Brunet; P Philip; A Chaib; R Costello
Journal:  J Clin Apher       Date:  2016-07-21       Impact factor: 2.821

7.  Continuous CD34+ cell collection by a new device is safe and more efficient than by a standard collection procedure: results of a two-center, crossover, randomized trial.

Authors:  Jose A Cancelas; Edward P Scott; Jerome R Bill
Journal:  Transfusion       Date:  2016-09-02       Impact factor: 3.157

8.  The influence of automated plateletpheresis on systemic levels of hematopoietic growth factors.

Authors:  V Weisbach; H Friedlein; A Glaser; J Zingsem; R Zimmermann; R Eckstein
Journal:  Transfusion       Date:  1999-08       Impact factor: 3.157

9.  First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors.

Authors:  P A Steininger; E F Strasser; D Weiss; S Achenbach; R Zimmermann; R Eckstein
Journal:  Vox Sang       Date:  2013-10-24       Impact factor: 2.144

10.  Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems.

Authors:  Miriam Schulz; Heike Bialleck; Kristin Thorausch; Gesine Bug; Ulrich Dünzinger; Erhard Seifried; Halvard Bönig
Journal:  Transfusion       Date:  2013-12-03       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.